The largest database of trusted experimental protocols

Antimouse nk1.1 pk136

Manufactured by BioXCell
Sourced in Germany

Antimouse NK1.1 (PK136) is a mouse monoclonal antibody that specifically binds to the NK1.1 antigen expressed on natural killer (NK) cells and a subset of T cells in mice. It is commonly used as a tool for the identification and isolation of NK cells in research applications.

Automatically generated - may contain errors

2 protocols using antimouse nk1.1 pk136

1

Characterizing Intrahepatic Immune Responses in Chronic HBV

Check if the same lab product or an alternative is used in the 5 most similar protocols
C57Bl/6 mice were purchased from Charles River (Sulzfeld, Germany). H‐2Kb‐restricted T‐cell receptor (TCR) transgenic CD45.1+ OT‐1 mice were bred and maintained under specific pathogen‐free conditions in the central animal facility of the Klinikum Rechts der Isar according to the guidelines of the Federation of Laboratory Animal Science Association. Male mice between the ages of 6 and 10 weeks were used. Cell depletion was injected intravenously with 30 µg antimouse CD8α (clone 2.43, BioXCell), 300 µg antimouse CD4 (GK1.5, BioXCell), or 300 µg antimouse NK1.1 (PK136, BioXCell).
Patients with the diagnosis of chronic HBV infection who presented at the University Medical Center Freiburg outpatient liver center were recruited in the study after obtaining written informed consent from each patient and approval by the Ethics Committee of the Albert Ludwigs University of Freiburg (Germany). Intrahepatic lymphocytes, obtained during diagnostic liver biopsy, were compared with peripheral immune responses and analyzed for HBV‐specific immune responses and expression of inhibitory receptors. All investigations were conducted according to the principles expressed in the Declaration of Helsinki.
+ Open protocol
+ Expand
2

Immune Cell Depletion and TIGIT Blockade

Check if the same lab product or an alternative is used in the 5 most similar protocols
For immune-cell depletion, anti-mouse CD8α (2.43; Bio X Cell, catalog no. BE0061) and rat IgG2b isotype control (LTF-2; Bio X Cell, catalog no. BE0090) were diluted to 100 μg/100 μL with pH 7.0 dilution buffer (Bio X Cell, catalog no. IP0070); anti-mouse CD4 (GK1.5; Bio X Cell, catalog no. BE0003-1) was diluted to 200 μg/100 μL with pH 6.5 dilution buffer (Bio X Cell, catalog no. IP0065); anti-mouse NK1.1 (PK136; Bio X Cell, catalog no. BE0036) was diluted to 200 μg/100 μL with pH 7.0 dilution buffer (Bio X Cell, catalog no. IP0070). Then the antibodies were intraperitonially injected into mice (100 μL/mouse) starting one day prior to tumor injection, followed by two more weekly doses. For TIGIT blockade, anti-mouse TIGIT (1B4; Absolute Antibody, catalog no. Ab01258-1.1) or mouse IgG1 isotype control (MOPC-21; Bio X Cell, catalog no. BE0083) were intraperitoneally injected into mice starting on day 4 after tumor injection followed by a serial four doses (200 μg/mouse) every 3 days, and a maintenance dose (100 μg/mouse) on day 20.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!